DDInter256 DDInter1702
Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.[A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.[A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Butabarbital {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Dermatitis exfoliative {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Butabarbital {u} (Compound) resembles {v} (Compound) Secobarbital
Secobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Butabarbital {u} (Compound) resembles {v} (Compound) Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Butabarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Butabarbital {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Dermatitis exfoliative {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sorafenib
Butabarbital {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Vismodegib {u} (Compound) resembles {v} (Compound) Sorafenib
Butabarbital {u} (Compound) resembles {v} (Compound) Secobarbital
Secobarbital {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sorafenib
Butabarbital {u} (Compound) resembles {v} (Compound) Butalbital
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sorafenib
Butabarbital {u} (Compound) resembles {v} (Compound) Phenobarbital
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Regorafenib {u} (Compound) resembles {v} (Compound) Sorafenib
Butabarbital {u} (Compound) resembles {v} (Compound) Amobarbital
Amobarbital {u} (Compound) resembles {v} (Compound) Secobarbital
Secobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Butabarbital (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfoliative (Side Effect) is caused by Sorafenib (Compound)
Butabarbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib
Butabarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib
Butabarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib
Butabarbital (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfoliative (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sorafenib
Butabarbital (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Vismodegib (Compound) and Vismodegib (Compound) resembles Sorafenib (Compound)
Butabarbital (Compound) resembles Secobarbital (Compound) and Secobarbital (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sorafenib (Compound)
Butabarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sorafenib
Butabarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib (Compound) resembles Sorafenib (Compound)
Butabarbital (Compound) resembles Amobarbital (Compound) and Amobarbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib